The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Prognostic factors in early breast carcinoma
Abstract
Several investigators, the SEER data, and the ECOG/Intergroup study have shown that patients with small tumors (<0.5 cm) have a recurrence rate of less than 2%, compared to 20–25% for large tumors (≥5 cm). Nuclear grade and tumor differentiation are established indicators; however, the interobserver lack of concordance has thwarted their use in clinical trials. The presence of peritumoral lymphatic and blood vessel invasion (PLBI) is associated with a relative risk of recurrence of 4.7. The predictive value of the presence of hormone receptors in tumors is associated with a favorable disease free and overall survival difference of 8–10%; however, this advantage is being eroded by the early appearance of other factors, such as the epidermal growth factor receptor (EGFR), proliferative capacity (S-phase), nuclear grade, and HER-2/neu oncogene. Concordance among the different methods of hormone-receptor assay (immune-cytochemical, sucrose gradient, and dextran-coated charcoal) is essential to refine the true value of these factors. DNA flow cytometry measurements of ploidy (DNA content) and S-phase fraction are the most characterized of the prognostic factors. There are conflicting reports regarding the clinical significance of ploidy status, while measurements of S-phase fraction clearly indicate a robust association with disease free and overall survival. Our data continue to show that S-phase, but not ploidy, can predict time to recurrence significantly in untreated patients, even when data are stratified for tumor size. HER-2/neu oncogene is expressed in about 50% of ductal carcinoma in situ and 14% of invasive ductal carcinoma. The presence of this oncogene at high copy number may be a useful independent marker of poor prognosis and may be associated with drug resistance and correlated with tumor recurrence and shorter survival. EGFR could be measured in most breast tumors, and the level of its expression has inversely correlated with estrogen receptor protein expression. The value of EGFR as a predictor of prognosis remains controversial and is still being investigated. Cathepsin-D provides a provocative biologic rationale but is hindered by different and incongruent methods of analysis. The majority of large studies with more than 3-years' follow-up suggests that high cathepsin-D levels may be predictive of greater recurrence and lower survival. Angiogenesis has been implicated as a critical component of the metastatic process. Early studies show that tumor angiogenesis is an independent and highly significant prognostic indicator, and its presence may suggest the selection of “anti-angiogenic therapy.” Mutations in the tumor suppressor p53 gene have been detected in 13–15% of primary breast cancers, resulting in overexpression of mutant p53, which is associated with poor prognosis. There also may be a strong relationship between mutant p53 overexpression and high S-phase activity. Although there is a growing understanding of the prognostic significance of individual prognostic factors, the topic of how practically to use multiple prognostic factors in concert is still largely unexplored. The development of practical systems for clinical application will require improvements in the areas of (1) standardization of methodologies and interlaboratory quality control for prognostic factor determinations, (2) definition of a limited set of prognostic markers that are independently predictive, and (3) staging systems or tools that integrate this information. Large studies based on cooperative group material and large data bases will play a vital role in this process.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138
Induction of angiogenesis during the transition from hyperplasia to neoplasia
Folkman, J., Watson, K., Ingber, D., & Hanahan, D. (1989) · Nature · doi:10.1038/339058a0 · Cited by 1,879
Cited by
Estrogen Receptor Null Mice: What Have We Learned and Where Will They Lead Us?
Couse, J. F., & Korach, K. S. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.3.0370 · Cited by 2,045
Prognostic Factors in Breast Cancer: College of American Pathologists Consensus Statement 1999
Fitzgibbons, P. L., Page, D. L., Weaver, D., Thor, A. D., Allred, D. C., Clark, G. M., Ruby, S. G., O'Malley, F., Simpson, J. F., Connolly, J. L., et al. (2000) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2000-124-0966-pfibc · Cited by 1,016
(2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.13.979 · Cited by 893
Oncogenes and Tumor Suppressor Genes
Lee, E. Y. H. P., & Muller, W. J. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a003236 · Cited by 508
Multistep carcinogenesis of breast cancer and tumour heterogeneity
Beckmann, M. W., Niederacher, D., Schnürch, H.-G., Gusterson, B. A., & Bender, H. G. (1997) · Journal of Molecular Medicine · doi:10.1007/s001090050128 · Cited by 299
Metadata
- Authors
- Mansour, E. G., Ravdin, P. M., & Dressier, L.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 1994-01
- Volume
- 74
- Issue
- S1
- Pages
- 381-400
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1978173438
- Cited by
- 199
- References
- 2
- FWCI
- 8.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prognostic factors in early breast carcinoma. https://app.cochat.ai/papers/10.1002/cncr.2820741326
- The paper
- Mansour, E. G., Ravdin, P. M., & Dressier, L. (1994). Prognostic factors in early breast carcinoma. Cancer. https://doi.org/10.1002/cncr.2820741326
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.